S, B., KM, S., AM, R., MEA, T., AY, E., HA, S., & EM, E. (2024). Evaluation of hepcidin-25/erythroferrone ratio as a potential biomarker for iron utility and erythropoiesis responsiveness to erythropoiesis-stimulating therapy in comparison to immature erythrocyte/reticulocyte parameters in hemodialysis patients. Hematology, transfusion and cell therapy, 46 Suppl 5, S214. https://doi.org/10.1016/j.htct.2024.04.125
Chicago Style (17th ed.) CitationS, Bakr, Salem KM, Rashed AM, Tantawy MEA, Elsary AY, Shamardl HA, and Ezzat EM. "Evaluation of Hepcidin-25/erythroferrone Ratio as a Potential Biomarker for Iron Utility and Erythropoiesis Responsiveness to Erythropoiesis-stimulating Therapy in Comparison to Immature Erythrocyte/reticulocyte Parameters in Hemodialysis Patients." Hematology, Transfusion and Cell Therapy 46 Suppl 5 (2024): S214. https://doi.org/10.1016/j.htct.2024.04.125.
MLA (9th ed.) CitationS, Bakr, et al. "Evaluation of Hepcidin-25/erythroferrone Ratio as a Potential Biomarker for Iron Utility and Erythropoiesis Responsiveness to Erythropoiesis-stimulating Therapy in Comparison to Immature Erythrocyte/reticulocyte Parameters in Hemodialysis Patients." Hematology, Transfusion and Cell Therapy, vol. 46 Suppl 5, 2024, p. S214, https://doi.org/10.1016/j.htct.2024.04.125.
